journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Psychopharmacology

journal
https://www.readbyqxmd.com/read/28348732/probuphine%C3%A2-buprenorphine-implant-a-promising-candidate-in-opioid-dependence
#1
REVIEW
Preeti Barnwal, Saibal Das, Somnath Mondal, Anand Ramasamy, Tanay Maiti, Arunava Saha
Opioid dependence leads to physical dependence and addiction which finally results in profound medical, psychological and social dysfunction. One of the useful medications for opioid dependence is buprenorphine, the partial opioid agonist, which is used alone or in combination with naloxone. However, buprenorphine is the victim of its own success due to its illicit use and accidental poisoning in children. Also, buprenorphine typically requires daily self-administration and its effectiveness heavily depends on patient adherence...
March 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28348731/clonazepam-improves-dopamine-supersensitivity-in-a-schizophrenia-patient-a-case-report
#2
REVIEW
Mina Fukai, Tetsu Hirosawa, Tetsuya Takahashi, Reizo Kaneda, Mitsuru Kikuchi, Yoshio Minabe
Dopamine supersensitivity is an important consideration for assessing treatment-resistant schizophrenia. The emergence of dopamine supersensitivity might be related to upregulation of dopamine D2 receptor, which engenders tolerance to antipsychotics, rebound psychosis, and tardive dyskinesia (TD). A 24-year-old man with a history of treatment-resistant schizophrenia was hospitalized for treatment of bone fracture sustained during a suicide attempt. After the operation, his clinical symptoms implied malignant catatonia...
March 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28348730/prescribing-pattern-of-clozapine-and-other-antipsychotics-for-patients-with-first-episode-psychosis-a-cross-sectional-survey-of-early-intervention-teams
#3
Tongeji E Tungaraza, Wakil Ahmed, Chinonyelum Chira, Erin Turner, Susan Mayaki, Harpal Singh Nandhra, Tom Edwards, Saeed Farooq
OBJECTIVE: To describe the pattern of antipsychotic drug prescribing in patients with first episode psychosis, with more emphasis in the use of clozapine in this group of patients. METHOD: A cross-sectional survey involving six early intervention service (EIS) teams in the West Midlands was conducted. Data was extracted from case notes and electronic records by clinicians working in each participating team. The pattern of antipsychotic prescribing and the changes that took place after being accepted in EIS, including the use of clozapine, was established...
March 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28344764/atypical-antipsychotics-recent-research-findings-and-applications-to-clinical-practice-proceedings-of-a-symposium-presented-at-the-29th-annual-european-college-of-neuropsychopharmacology-congress-19-september-2016-vienna-austria
#4
REVIEW
Robin Murray, Christoph U Correll, Gavin P Reynolds, David Taylor
Available evidence suggests that second-generation atypical antipsychotics are broadly similar to first-generation agents in terms of their efficacy, but may have a more favourable tolerability profile, primarily by being less likely to cause extrapyramidal symptoms. However, atypical antipsychotics are variably associated with disturbances in the cardiometabolic arena, including increased body weight and the development of metabolic syndrome, which may reflect differences in their receptor binding profiles...
March 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28255440/interaction-between-clozapine-and-oxcarbazepine-a-case-report
#5
Hazel Yousra, Lebain Pierrick, Lecardeur Laurent, Debruyne Danièle
No abstract text is available yet for this article.
February 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28255439/case-report-of-a-switch-to-mania-induced-by-lurasidone
#6
Mark Kanzawa, Olga Hadden
No abstract text is available yet for this article.
February 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28255438/lactate-in-the-brain-an-update-on-its-relevance-to-brain-energy-neurons-glia-and-panic-disorder
#7
REVIEW
Laurel Riske, Rejish K Thomas, Glen B Baker, Serdar M Dursun
Lactate is considered an important metabolite in the human body, but there has been considerable debate about its roles in brain function. Research in recent years has suggested that lactate from astrocytes may be crucial for supporting axonal function, especially during times of high metabolic demands or hypoglycemia. The astrocyte-neuron lactate transfer shuttle system serves a protective function to ensure a supply of substrates for brain metabolism, and oligodendrocytes appear to also influence availability of lactate...
February 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28255437/effects-of-a-smoking-ban-on-clozapine-plasma-concentrations-in-a-nonsecure-psychiatric-unit
#8
Siobhan H Gee, David M Taylor, Sukhwinder S Shergill, Robert Flanagan, James H MacCabe
BACKGROUND: Tobacco smoke is known to affect plasma levels of some drugs, including the antipsychotic clozapine. The effects of suddenly stopping smoking on patients who take clozapine can be severe, as plasma concentrations are expected to rapidly rise, potentially leading to toxicity. A ban on smoking at South London and the Maudsley NHS Foundation Trust (SLaM) was implemented in 2014, and this was expected to affect the plasma concentrations of clozapine for inpatients at the time...
February 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28255436/does-the-efficacy-of-asenapine-in-bipolar-disorder-increase-in-the-presence-of-comorbidity-with-a-substance-use-disorder-a-naturalistic-study
#9
Sergio De Filippis, Ilaria Cuomo, Georgios D Kotzalidis, Daniela Pucci, Pietro Zingaretti, Raffaella Porrari, Camilla Fini, Paola Motta, Matteo Caloro, Paolo Girardi
BACKGROUND: Asenapine is a second-generation antipsychotic approved in Europe for treating moderate-to-severe manic episodes in adults affected by type I bipolar disorder (BD-I). We aimed to compare its efficacy in psychiatric inpatients with BD-I, with or without substance use disorder (SUD). METHODS: We administered flexible asenapine doses ranging from 5-20 mg/day to 119 voluntarily hospitalized patients with Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) BD-I diagnosis, with or without SUD...
February 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28255435/the-effect-of-long-acting-paliperidone-palmitate-once-monthly-on-negative-and-depressive-symptoms-in-patients-with-schizophrenia-switched-from-previous-unsuccessful-treatment-with-oral-aripiprazole
#10
Andreas Schreiner, Paul Bergmans, Pierre Cherubin, Ludger Hargarter
BACKGROUND: The negative symptoms of schizophrenia are generally harder to recognize, more difficult to treat than positive symptoms, and have a significant impact on patient functioning and overall outcomes. Treatment with aripiprazole may be associated with benefits on negative symptoms and functioning given its partial agonism to the dopamine D2 receptor. The aim of this subanalysis was to explore the impact of flexibly dosed, long-acting paliperidone palmitate once monthly (PP1M) on negative and depressive symptoms, disorganized thoughts, anxiety, extrapyramidal symptoms, and patient functioning in nonacute adult patients with schizophrenia previously unsuccessfully treated with oral aripiprazole monotherapy...
February 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28101325/role-of-psilocybin-in-the-treatment-of-depression
#11
Ananya Mahapatra, Rishi Gupta
Psilocybin is a naturally occurring alkaloid, pharmacologically similar to the classic hallucinogen lysergic acid diethylamide (LSD). Although primarily used as a recreational drug or an entheogen in particular cultural settings, recent population based studies have shown that it does not lead to serious physical or mental health problems or dependent use. In view of recent work demonstrating psilocybin's potential to increase subjective sense of wellbeing and because of its novel mechanism of 5-HT2A serotonin receptor agonism, it is being explored for possible therapeutic utility in mood and anxiety disorders...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28101324/oxytocin-for-frontotemporal-dementia-a-systematic-review
#12
REVIEW
Rajesh R Tampi, Michael Maksimowski, Mohsina Ahmed, Deena J Tampi
BACKGROUND: The aim of this systematic review is to identify published randomized controlled trials (RCTs) that evaluated the use of oxytocin in individuals with frontotemporal dementia (FTD). METHODS: A literature search was conducted of PubMed, MEDLINE, EMBASE, PsycINFO and Cochrane collaboration databases for RCTs in any language that evaluated the use of oxytocin in individuals with FTD. Bibliographic databases of published articles were also searched for additional studies...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28101323/gabapentin-treatment-in-clozapine-induced-restless-legs-syndrome-two-cases-and-a-review-of-the-literature
#13
REVIEW
Vijaya Kumar, Ganesan Venkatasubramanian
Restless legs syndrome (RLS) is a neuro-sensorimotor disorder affecting 2-4% of adults. It is characterized by intense urges to move the legs, associated with unpleasant sensory disturbances in the legs occurring at rest and manifests mostly in the evening and night, relieved by movement. Diagnosis is primarily based on clinical presentation and the consensus criteria for the diagnosis have been established. Antipsychotics, the dopamine antagonists, have been reported to induce RLS. Dopamine agonists, the effective first-line treatment of RLS, carry the risk of inducing or worsening psychosis...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28101322/brexpiprazole-and-cariprazine-distinguishing-two-new-atypical-antipsychotics-from-the-original-dopamine-stabilizer-aripiprazole
#14
REVIEW
Joshua S Frankel, Thomas L Schwartz
BACKGROUND: Brexpiprazole and cariprazine are the latest US Food and Drug Administration approved atypical antipsychotics available in the United States. Both function as partial agonists of the dopamine-2 receptor (D2R), a mechanism of action shared with aripiprazole. However, all three differ in their affinities for the D2R as well as for serotonin receptors (5-HTRs). This paper seeks to delineate these pharmacodynamic and clinical differences amongst the three dopamine partial agonist atypical antipsychotic drugs...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28101321/switching-away-from-pipotiazine-palmitate-a-naturalistic-study
#15
Feras Ali Mustafa
BACKGROUND: In March 2015, pipotiazine palmitate depot antipsychotic was globally withdrawn due to the shortage of its active ingredient. Thus, all patients receiving this medication had to be switched to an alternative antipsychotic drug. In this study we set to evaluate the process of switching away from pipotiazine palmitate within our clinical service, and its impact on hospitalization. METHODS: Demographic and clinical data on patients who were receiving pipotiazine palmitate in Northamptonshire at the time of its withdrawal were anonymously extracted from their electronic records and analyzed using descriptive statistics...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28101320/variation-in-dose-and-plasma-level-of-lamotrigine-in-patients-discharged-from-a-mental-health-trust
#16
Petrina Douglas-Hall, Olubanke Dzahini, Fiona Gaughran, Ahmed Bile, David Taylor
BACKGROUND: The objectives of this study were to investigate the dose of lamotrigine when prescribed with an enzyme inhibitor or enzyme inducer in patients discharged from a mental health trust and to determine the corresponding lamotrigine plasma concentrations and the factors that may affect these. METHODS: All patients discharged on lamotrigine between October 2007 and September 2012 were identified using the pharmacy dispensing database. We recorded demographic details, lamotrigine dose and plasma levels and coprescribed medication...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28101319/the-nursing-assessment-of-medication-acceptance-the-reliability-and-validity-of-a-schizophrenia-medication-adherence-scale
#17
Hikaru Hori, Nobuhisa Ueda, Hideki Shiozuka, Ryohei Igata, Tazuko Miki, Kiyokazu Atake, Yuji Takeuchi, Hiroaki Shirozu, Naotoshi Ohara, Yuki Konishi, Hiroshi Nagai, Noriaki Sakurai, Takanori Kubota, Reiji Yoshimura
BACKGROUND: Many patients with schizophrenia have low medication adherence. There is, however, no objective assessment scale that can be used by nurses or caregiver specialists. The Nursing Assessment of Medication Acceptance (NAMA) was developed to assess patients' medication adherence. The aim of this study was to examine the validity and reliability of the NAMA in patients with schizophrenia. METHODS: A total of 121 Japanese patients with schizophrenia were enrolled...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28101318/prevalence-and-correlates-of-antipsychotic-polypharmacy-among-outpatients-with-schizophrenia-attending-a-tertiary-psychiatric-facility-in-nigeria
#18
Nosa Godwin Igbinomwanhia, Sunday Osasu Olotu, Bawo Onesirosan James
BACKGROUND: The study aimed to determine the prevalence, pattern and correlates of antipsychotic polypharmacy (APP) among outpatients with schizophrenia attending a tertiary psychiatric facility in Nigeria. METHOD: A cross-sectional study of 250 patients with schizophrenia attending the outpatient clinic of a regional tertiary psychiatric facility in Nigeria was undertaken. They were administered a sociodemographic questionnaire, the Positive and Negative Syndrome Scale (PANSS), the Global Assessment of Functioning (GAF) scale and the Liverpool University Side Effects Rating Scale (LUNSERS)...
January 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28008352/low-dose-quetiapine-complements-stimulant-response-in-attention-deficit-hyperactivity-disorder-and-more
#19
Ahmed Naguy
No abstract text is available yet for this article.
December 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28008351/methamphetamine-addiction-potential-substitute-treatment
#20
Florence Levy
No abstract text is available yet for this article.
December 2016: Therapeutic Advances in Psychopharmacology
journal
journal
43489
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"